This HTML5 document contains 62 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n21http://linked.opendata.cz/resource/drugbank/drug/DB04552/identifier/pubchem-substance/
n10http://linked.opendata.cz/resource/drugbank/drug/DB04552/identifier/drugbank/
n16http://linked.opendata.cz/resource/mesh/concept/
n19http://linked.opendata.cz/resource/drugbank/drug/DB04552/identifier/iuphar/
n11http://linked.opendata.cz/resource/drugbank/drug/DB04552/identifier/guide-to-pharmacology/
n9http://bio2rdf.org/drugbank:
n12http://linked.opendata.cz/resource/drugbank/drug/DB04552/identifier/chemspider/
admshttp://www.w3.org/ns/adms#
n22http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n15http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n7http://linked.opendata.cz/resource/drugbank/drug/DB04552/identifier/pharmgkb/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n20http://linked.opendata.cz/resource/drugbank/drug/DB04552/identifier/kegg-compound/
n17http://linked.opendata.cz/resource/drugbank/drug/DB04552/identifier/pdb/
n18http://linked.opendata.cz/resource/drugbank/drug/DB04552/identifier/pubchem-compound/
n14http://linked.opendata.cz/resource/atc/
n13http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB04552
rdf:type
n3:Drug
n3:description
An analgesic and anti-inflammatory agent used in the treatment of rheumatoid arthritis. [PubChem]
n3:generalReferences
# Criddle DN, de Moura RS, Greenwood IA, Large WA: Inhibitory action of niflumic acid on noradrenaline- and 5-hydroxytryptamine-induced pressor responses in the isolated mesenteric vascular bed of the rat. Br J Pharmacol. 1997 Mar;120(5):813-8. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/9138686
n3:group
approved
n3:halfLife
2.5 hours
n3:indication
Used in the treatment of rheumatoid arthritis.
owl:sameAs
n9:DB04552 n22:DB04552
dcterms:title
Niflumic Acid
adms:identifier
n7:PA164746749 n10:DB04552 n11:2439 n12:4333 n17:NFL n18:4488 n19:2439 n20:C13698 n21:46504657
n3:mechanismOfAction
Niflumic acid is able to inhibit both phospholipase A2 as well as COX-2, thereby acting as an antiinflamatory and pain reduction agent.
n3:synonym
Niflugel Acide niflumique Acido niflumico NFA Acidum niflumicum
n3:toxicity
Oral, mouse: LD<sub>50</sub> = 350 mg/kg; Oral, rat: LD<sub>50</sub> = 250 mg/kg
n3:proteinBinding
90% bound to plasma proteins.
n15:hasConcept
n16:M0014850
n3:IUPAC-Name
n4:271B649A-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B64A0-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B649F-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B649C-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B649D-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B649E-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B6498-363D-11E5-9242-09173F13E4C5 n4:271B64B0-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B6499-363D-11E5-9242-09173F13E4C5 n4:271B64B2-363D-11E5-9242-09173F13E4C5 n4:271B6496-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B6497-363D-11E5-9242-09173F13E4C5
n13:hasATCCode
n14:M01AX02 n14:M02AA17
n3:H-Bond-Acceptor-Count
n4:271B64A6-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B64A7-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B64A1-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B64A2-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B64A4-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B64A3-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B64A5-363D-11E5-9242-09173F13E4C5
n3:absorption
Well absorbed following oral administration.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
4394-00-7
n3:category
n3:Bioavailability
n4:271B64AC-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B64AE-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B64AF-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B64B1-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B64AB-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B64AA-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B64AD-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B649B-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B64A8-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B64A9-363D-11E5-9242-09173F13E4C5